Clinical Trials of Multivalent Opioid Vaccine Components (Group 1)
Clinical Trials of Multivalent Opioid Vaccine Components (Healthy individuals who use heroin or other opioids)
Sponsor: National Institute on Drug Abuse
Enrolling: Male and Female Patients
Study Length: 96 Weeks
Clinic Visits: 33
IRB Number: 7712-1
U.S. Govt. ID: NCT04458545
Contact: Rachel Luba: 646-774-6243 / rrl2117@cumc.columbia.edu
Additional Study Information: Do you use Heroin or Opioids? Physically-dependent healthy individuals who use heroin or other opioids are needed for an outpatient research study at the New York State Psychiatric Institute. Earn up to $7,350 for your participation. Call 646-774-6243. Screening Procedures Include: 3-5 screening visits to determine eligibility ($75 per visit). If Eligible, Study Procedures Include: Regular study visits for 21 weeks , continued study visits from weeks 21-96 (every 4-6 weeks), regular assessment of physical health (ECG, vitals, bloodwork), Psychiatric Assessments, and Questions about side effects and new medications.
This study is closed
Investigator
Sandra Comer, PhD
Do You Qualify?
Are you currently using heroin or other opioids? Yes No
Are you between 18 and 59 years old? Yes No
Are you pregnant or breastfeeding? Yes No
Have you ever used opioids intranasally (through your nose)? Yes No
Are you willing to receive an experimental vaccine for opioid use disorder? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder




For more information, please contact:
Rachel Luba
rrl2117@cumc.columbia.edu
646-774-6243